Ticker Symbol: CUR
QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two of DiagnoCure Inc. (TSX: CUR) products, the PCA3 marker for the detection of prostate cancer and GCC for the staging of colorectal cancer, were discussed at recent scientific meetings as part of the growing trend to molecular diagnostics.
Yesterday, on June 2nd, DiagnoCure opened the sessions at the 34th Annual International Clinical Ligand Assay Society Meeting, held in Coral Springs, Florida, with a presentation on its guanylyl cyclase C (GCC) testing research.
Timothy J. Holzer, Ph.D., Vice President, R&D and Production at DiagnoCure, presented research data on "Molecular Detection of Colorectal Cancer Lymph Node Micrometastasis". Dr. Holzer's presentation featured a statistical review and discussion of the beneficial role of GCC in the staging of colorectal cancer.
GCC is expressed only in intestinal mucosal cells, but not in extra-intestinal tissues. In addition, GCC is expressed in colorectal tumors, but not in other cancers outside the gastro-intestinal tract. Therefore, GCC may be useful clinically for the management of patients with colorectal cancer in providing more accurate information to physicians and patients and influencing treatment decisions.
In a review of a prototype colorectal cancer staging test in its Quebec facility utilizing nearly 1,500 lymph nodes, a DiagnoCure's study demonstrated that in patients previously staged as having no positive lymph nodes (Stage II), 30 percent had at least one lymph node with GCC expression at least as high as that found in lymph nodes called positive by a pathologist (Stage III). This would indicate that these patients should be considered for cancer management equal to that for a Stage III patient.
During the same event, the PCA3-based test was also featured in a presentation by Ina Deras, Ph.D., Senior Research Scientist at Gen-Probe Inc., titled "PCA3 as a Biomarker for Prostate Cancer Disease Stratification".
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, which is ending today, DiagnoCure is introducing Previstage(TM) GCC, a molecular diagnostic solution for the need to more accurate staging of colorectal cancer, to the medical community. Attending key opinion leaders from the colorectal cancer treatment community expressed great interest in DiagnoCure's Previstage(TM) GCC test. The ASCO meeting is host to over 30,000 health practitioners concerned with cancer.
At the meeting of the American Urological Association (AUA) in Orlando, Florida, the PCA3 marker-based test was the subject of several presentations and three exhibits. The meeting was at ended by over 10,000 urologists from around the world. Gen-Probe Incorporated, DiagnoCure's commercialization partner for PCA3, featured the test in its exhibition booth, and Dianon (LabCorp) and AmeriPath (Quest) had their versions of the test prominently featured as well.
During this key annual meeting, Dr. Yves Fradet, Founder and Chief Medical Officer of DiagnoCure, participated in a panel of three researchers who discussed their investigations on "The Evolution of Markers for Urologic Cancer". Dr. Fradet presented the promising latest clinical findings on PCA3 to an audience of approximately 1,000 people. The discussion was led by Dr. Peter T. Scardino who spoke highly of the PCA3 marker in an AUA Daily News article.
DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit http://www.diagnocure.com.
This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
|SOURCE DIAGNOCURE INC.|
Copyright©2008 PR Newswire.
All rights reserved